MDACC Study No:2011-0144 ( NCT No: NCT01372540)
Title:A Phase I Study of Arry-520 and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
Principal Investigator:Jatin J. Shah
Treatment Agent:ARRY-520; Carfilzomib
Study Status:Open
Study Description:This study is divided into study groups, as described below. The goal of
Groups 1A and 2A of this clinical research study is to find the highest
tolerable dose of the combination of ARRY-520 and carfilzomib that can be given
to patients with multiple myeloma or plasma cell leukemia.

The goal of Groups 1B and 2B of this study is to learn if the combination of
carfilzomib and ARRY-520 can help to control multiple myeloma or plasma cell
leukemia. Researchers would also like to learn if ARRY-520 can help
carfilzomib to work in patients who have built up a resistance to carfilzomib
or carfilzomib alone has not helped to control the disease.

The safety of the study drugs will be studied in all groups.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I
Treatment Agents:ARRY-520
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Array Bio Pharma
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults